Blog - FDA Map

FDA Purán

Our Unique Perspective on News of Global Pharma & Healthcare Industry

Latest News

Tap the Headlines Below to Explore the News

Newsletter, July 16, 2026

FDA’s New OTC Monograph Guidance: Transforming Regulatory Conversations into Public Records

Designing the Un-blindable Study: Your Guide to the FDA’s Psychedelic Trial Rules

Newsletter, July 2, 2026

Smarter, Faster, Unified: How to Leverage the Latest FDA Master Protocol Framework

The Flexible BLA: How the FDA is Rewriting the Rules for Cell and Gene Therapies

Newsletter, June 25, 2026

De-Risking Flexibilities: How to Move Frontline FDA Reviewers from ‘No’ to ‘Yes’

Falsified Reports, Real Consequences: The Regulatory Danger of Third-Party Lab Fraud

Newsletter, June 18, 2026

The New Era of Payor Communication: Five Crucial Takeaways from the FDA’s New Communications Draft

The FDA’s New Playbook for Clinical Immunogenicity Data

Newsletter, June 11, 2026

The Price of Speed: What Cancer Patients Really Think About Fast-Tracked Drugs

Why We Buy Wearables but Hide the Data From Our Doctors

Newsletter, June 04, 2026

The $100M Shortcut: Mastering the FDA’s New Rules for Virtual Drug Development

Data, Risk, and Digitalization: Navigating the FDA’s Unified Quality Paradigm

Newsletter, May 28, 2026

Importing Under the Microscope: What 6 Recent FDA Warning Letters Teach Us

The FDA’s New 5-Part Plan: Shifting the Focus from Opioids to Safer Pain Relief

Newsletter, May 21, 2026

The TEMPO Pilot: The FDA’s New Regulatory Sandbox for Digital Health Innovations

Food-Effect Trials: Aligning INDs and NDAs with CDER Expectations

Newsletter, May 14, 2026

When Your Doctor’s “Consultant” is an Algorithm: The Rise of Shadow AI in Clinics

FDA Pushes for Postapproval Pregnancy Data

Newsletter, May 7, 2026

The Rise of Elsa: Why the FDA is Betting Big on Artificial Intelligence

The Lean Inspection: Can the FDA Do More with Less Time?

Newsletter, April 30, 2026

Accelerating the Path from Database Lock to Market Entry: FDA’s New Real Time Trial Program

The Latest FDA Infant Formula Testing Data: Quantifying Chemical Contaminants in the Supply Chain

Newsletter, April 23, 2026

Mastering the FDA’s New Expanded Access Framework: Expanded Access vs. Right to Try

Decoding the FDA’s New NGS Safety Framework for the Gene Therapy Products

Newsletter, April 16, 2026

FDA’s New Risk-Based Inspection Program for Medical Devices: Lessons for Drug Facilities

How “Plausible Mechanism” Codifies the Single-Trial Pivot

Newsletter, April 9, 2026

Navigating the Hallucination Risks of Regulatory AI

From In silico to In vivo: Orchestrating AI for Breakthrough Therapeutics

Newsletter, April 2, 2026

The Lean IND: Operationalizing the "Least Burdensome" Mandate

Beyond the P-Value: Navigating the FDA’s New Bayesian Guidance for Drugs and Biologics

Newsletter, March 26, 2026

3D Printing and Solid Oral Dosage Forms: Navigating EMA and FDA Roadmaps

Beyond the LAL: Critical Updates to Bacterial Endotoxins and Pyrogen Testing

Newsletter, March 19, 2026

De-risking Drug Development with Fit-for-Purpose Non-Animal Models

FDA’s Transition to a Unified Adverse Event Framework

Newsletter, March 12, 2026

Strategic Response Management: Aligning 483 Remediation

Navigating the New Regulatory Framework for Biosimilars: FDA Slashes PK Hurdles and Streamlines the Biosimilar Pipeline

Newsletter, March 5, 2026

From Real-World Data to Regulatory Action: Understanding FDA’s ICH M14 Guidance

Unlocking the FDA’s 3-Year Exclusivity: What Drug Developers Need to Know

Newsletter, Feb 26, 2026

From Orphan Drugs to Individualized Medicine: Navigating the New FDA Guidance

BESH Reimagined: How New NIH Rules Impact Your Next Grant Application

Newsletter, Feb 19, 2026

The Single-Trial Pivot: What the FDA’s One-Study Standard Means for Your Pipeline

FDA Streamlines Device Review with 2026 Consensus Standard Updates

Newsletter, Feb 12, 2026

Beyond Endpoints: FDA’s Framework for Clinical Trials to Quantify What Patients Value

AI Meets Regulation: Key Takeaways from FDA’s AI Draft Guidance and ICH M15 Principles

Newsletter, Feb 5, 2026

FDA Compliant Postmarket Drug Safety: Insights From the Latest JAMA Analysis

From Offshore to Onshore: How FDA PreCheck Could Reshape U.S. Drug Supply

Newsletter, Jan 15, 2026

FDA and EMA’s List their Requirements for AI-Medical Devices

What FDA’s New Guidance on Bayesian Statistics Means for Drug Developers?

Newsletter, Jan 8, 2026

From Fitness Trackers to Apps: How FDA Defines Low-Risk Wellness Products

FDA Defines When A Clinical Decision Support Software Become a Medical Device

Newsletter, Dec 11, 2025

The FDA Just Rewrote the CAR-T Rulebook – Quietly

Regulatory Considerations for Biosimilar Promotion

Newsletter, Dec 4, 2025

FDA Encourages Non-Animal Methods in Monoclonal Antibody Safety Testing

New eCopy Rules — What Companies Must Know.

Newsletter, Nov 20, 2025

FDAMap’s Strategy for Personalized Stem Cell Therapy in the GCC

FDAMap Expands Regenerative Stem Cell Therapy Initiatives in South America

Newsletter, Nov 13, 2025

The Hidden Flaw in FDA-Approved AI Medical Devices

Real-World Evidence in EMA Drug Approvals

Newsletter, Nov 6, 2025

Keep Submitting: The FDA Review Clock is Ticking During the Shutdown

The FDA Refuse to File Checklists: Your Guide to a First-Cycle Approval

Newsletter, Oct 30, 2025

Will AI Terminate Human Medical Writers?

When Comparative Efficacy Studies Aren’t Needed for Biosimilars

Newsletter, Oct 23, 2025

Compassionate Use vs. Right to Try: Which Path Saves More Lives?

FDA’s PFDD Guidance: Turning Patient Voices into Regulatory Evidence

Newsletter, Oct 16, 2025

Is There Still A Good Scientific Justification for Animal Testing for New Drugs?

Pivoting Through Politics: A Strategic Guide for Vaccine Developers

Newsletter, Oct 9, 2025

FDA’s Domestic Push: PreCheck and the Global Reality of Generic Drugs

Data Integrity in Drug Trials: What the FDA’s GCP Inspection Data Reveals

Newsletter, Oct 2, 2025

ICH E20 vs. FDA 2019: Global Adaptive Trial Standards Redefined

Cosmeceuticals and Supplements: The Pseudo-Science Behind the Labels

Newsletter, Sept 25, 2025

FDA Two Guidances Try to Bridge Clinical Trials for Cell Therapy Products

Expedited FDA Approval of Stem Cell Therapies

Newsletter, Sept 18, 2025

FDA Guidance Embraces Hybrid Inspection Model for GMP Facilities

Study Highlights Challenges with Externally Controlled Trials

Newsletter, Sept 11, 2025

“What Happens When FDA’s Representations May Be False Or Misleading?”: Not Much

Risk-Based, Flexible, Modern: Inside the ICH E6(R3) GCP Guidance

Newsletter, Sept 4, 2025

New Regulatory Strategy for Ultra-rare Disease Products

Illinois Bans AI Therapy: What It Means for the Future of Mental Health Apps

Newsletter, Aug 28, 2025

From Turmeric to Tea: Why Natural Products Deserve a Fairer Conversation

Daily FAERS Data: The FDA’s Promise of Transparency—But at What Risk?

Newsletter, Aug 21, 2025

New FDA Guidelines Aim to Strengthen Survival Data in Oncology Drug Approvals

Inside the FDA’s Fast-Track Program for Medical Devices

Newsletter, Aug 14, 2025

Food as Medicine: How Culinary Clinics Are Changing Healthcare

Embryonic Stem Cells and mRNA Vaccines

Newsletter, July 31, 2025

How Registration Can Rescue Observational Studies from Bias and Hype

FDA’s White Paper Emphasizes that Quality Pays

Newsletter, July 24, 2025

EHRs Weren’t Built for Science — Here’s How to Fix That

How the FDA and Doctors Can Reassure Patients About AI

Newsletter, July 17, 2025

FDA Ends $800 Exemption—Here’s What Importers Need to Know

The Case Against 2:1 Randomization: Why Equal Allocation Still Wins

Newsletter, July 10, 2025

FDA’s 2025 Cybersecurity Guidance: What Every Medical Device Manufacturer Must Know

How to Get FDA Approval for Critical Antibiotics?

Newsletter, June 26, 2025

America’s Science Meltdown—And the Opportunity Rising From the Ashes

New FDA Crackdown on Overseas Cell Trials: Policy or Political Theater?

Newsletter, June 19, 2025

FDA’s CNPV Program Aims to Revolutionize Drug Reviews — But Will It Deliver?

Clinical Trial Without IND for a Supplement Gets Warning Letter

Newsletter, June 12, 2025

NIH’s Ambitious AI Strategy: Visionary or Overreach?

When Drug Criticism Slides into Conspiracism

Newsletter, June 5, 2025

ChatGPT Has a Little Sister, Her Name is Elsa, and She Lives at the FDA

FDA Spent 20 Years Chasing LDTs and a Federal Court Pulled the Plug Permanently

Newsletter, May 29, 2025

Why Many FDA-Approved AI Devices Fall Short in the Clinic.

Single-Arm Studies for Cancer Drug Approvals: FDA Hesitates to Create Precedent

Newsletter, May 22, 2025

HHS and FDA Aim Big Use of Big Data in Medicine: Genius or Wishful Thinking?

The End of Animal Testing? New FDA Rules Aim to Transforming Drug Development

Newsletter, May 15, 2025

HHS and FDA Launch Bold Drive to Cut Regulations

FDA to Use ChatGPT-Like LLMs for Application Reviews

Newsletter, May 8, 2025

Manufacturing Drugs in the US: The Real Challenge

FDA to Increase Unannounced Foreign GMP Inspections

Newsletter, May 1, 2025

NIH Joins FDA’s Move Toward Lesser Animal Testing

Clinical Trials Meet Real-World Data

Newsletter, April 24, 2025

Using Historical Controls for FDA Approval of Medical Devices

Why the PDUFA Program is Vital for FDA Drug Approvals—and Patient Lives

Newsletter, April 17, 2025

FDA Signals Reduced Emphasis on Animal Testing For Drug Approvals

Sex-Specific Data in Medical Device Trials: FDA’s Latest Guidance Document

Newsletter, April 10, 2025

EMA Advice on How to Use Real World Data

LDTs are Back: This Time it May be for Good

Newsletter, March 27, 2025

Why Randomized Trials Matter: The Case for Controlled Trials

FDA Flags Serious Data Falsification at a Chinese Medical Device Testing Facility